Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based, vertically integrated medical technology company focused on developing and commercializing novel technologies for weight loss. Obalon has launched the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
|Fourth Quarter 2017 Press Release|
|Third Quarter 2017 10Q|
OBLN (Common Stock) $3.75 - 0.09 (2.34%)
Data provided by Nasdaq. Minimum 15 minutes delayed.
Obalon Schedules Fourth Quarter and Year End 2017 Financial Results Conference Call for March 5, 2018 at 5:00 p.m. Eastern Time
Obalon Announces Fourth Quarter and Full Year 2017 Financial Results
Obalon’s Audit Committee Investigation of Whistleblower Allegation Finds Complaint Meritless
Obalon Announces Termination of Public Offering of Common Stock
|There are currently no events scheduled.|